{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:28:44Z","timestamp":1778858924812,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Research Section, All India Institute of Medical Sciences, New Delhi","award":["A-705"],"award-info":[{"award-number":["A-705"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors have revolutionized treatment of platinum-refractory advanced bladder cancer, offering hope where options are limited. Response varies, however, influenced by factors such as the tumor\u2019s immune microenvironment and prior therapy. Muscle-invasive bladder cancer (MIBC) is stratified into molecular subtypes, with distinct clinicopathologic features affecting prognosis and treatment. This study assessed the expression of programmed cell death 1 ligand 1 (PD-L1) and other immune markers in MIBC, categorized by molecular phenotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using GATA3 and CK5\/6 immunohistochemistry, 90 neoadjuvant chemotherapy\u2013naive MIBC cases were classified into luminal and non-luminal subtypes. The immune microenvironment was characterized through immunostaining for PD-L1, CD4, and CD8. We applied PD-L1 positivity thresholds of 1% or greater for tumor cells and 5% or greater for immune cells. Tumors were examined for PD-L1 expression, histologic subtypes, and immune cell infiltration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Varied expression of PD-L1 and T-cell subtype densities were observed among MIBC subtypes. The double-negative subtype displayed the highest PD-L1 immune cell expression and stromal CD4 and CD8 T-cell densities, indicating an active immune profile. The basal subtype exhibited the highest PD-L1 positivity in tumor cells. In contrast, the luminal type showed the lowest PD-L1 tumor and immune cell expression, with high intratumoral CD4 T-cell density. Although PD-L1 expression in tumor or immune cells did not independently affect survival, patients with basal and double-negative tumors had poorer overall survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study highlighted the immune diversity of MIBC in the context of molecular subtypes. Distinct molecular and immune profiles could guide the development of predictive signatures for enhanced immunotherapy response in advanced bladder cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqae176","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T22:50:46Z","timestamp":1736808646000},"page":"708-722","source":"Crossref","is-referenced-by-count":5,"title":["Comparative evaluation of PD-L1 expression and tumor immune microenvironment in molecular subtypes of muscle-invasive bladder cancer and its correlation with survival outcomes"],"prefix":"10.1093","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9407-999X","authenticated-orcid":false,"given":"Hena","family":"Khandakar","sequence":"first","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amlesh","family":"Seth","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit K","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology (Dr B. R. Ambedkar Institute Rotary Cancer Hospital), All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anubhav","family":"Narwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemlata","family":"Jangir","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brusabhanu","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit K","family":"Dinda","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"12","key":"2025052712494033000_CIT0001","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2025052712494033000_CIT0002","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","article-title":"Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification","volume":"242","author":"Sj\u00f6dahl","year":"2017","journal-title":"J Pathol."},{"issue":"2","key":"2025052712494033000_CIT0003","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"2025052712494033000_CIT0004","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell."},{"issue":"7492","key":"2025052712494033000_CIT0005","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature."},{"issue":"4","key":"2025052712494033000_CIT0006","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol."},{"issue":"6","key":"2025052712494033000_CIT0007","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1756287215607418","article-title":"Muscle-invasive urothelial bladder cancer: an update on systemic therapy","volume":"7","author":"Knollman","year":"2015","journal-title":"Ther Adv Urol"},{"issue":"10031","key":"2025052712494033000_CIT0008","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet."},{"issue":"3","key":"2025052712494033000_CIT0009","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10064","key":"2025052712494033000_CIT0010","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet."},{"issue":"5","key":"2025052712494033000_CIT0011","doi-asserted-by":"publisher","first-page":"e1134412","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"issue":"12","key":"2025052712494033000_CIT0012","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1245\/s10434-019-07529-y","article-title":"Prognostic role of the Immunoscore for patients with urothelial carcinoma of the bladder who underwent radical cystectomy","volume":"26","author":"Li","year":"2019","journal-title":"Ann Surg Oncol."},{"issue":"10122","key":"2025052712494033000_CIT0013","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet."},{"issue":"4","key":"2025052712494033000_CIT0014","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol."},{"key":"2025052712494033000_CIT0015","volume-title":"Urinary and Male Genital Tumours. WHO Classification of Tumours.","author":"WHO Classification of Tumours Editorial Board","year":"2022"},{"key":"2025052712494033000_CIT0016","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"8","key":"2025052712494033000_CIT0017","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"2025052712494033000_CIT0018","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"2025052712494033000_CIT0019","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep."},{"issue":"8","key":"2025052712494033000_CIT0020","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"2025052712494033000_CIT0021","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.eururo.2015.07.021","article-title":"On molecular classification of bladder cancer: out of one, many","volume":"68","author":"Aine","year":"2015","journal-title":"Eur Urol."},{"issue":"2","key":"2025052712494033000_CIT0022","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol."},{"issue":"8","key":"2025052712494033000_CIT0023","first-page":"2754","article-title":"Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture","volume":"36","author":"Herr","year":"1976","journal-title":"Cancer Res."},{"issue":"8","key":"2025052712494033000_CIT0024","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer."},{"issue":"40","key":"2025052712494033000_CIT0025","doi-asserted-by":"publisher","first-page":"66849","DOI":"10.18632\/oncotarget.19913","article-title":"PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy","volume":"8","author":"Pichler","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2025052712494033000_CIT0026","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2025052712494033000_CIT0027","doi-asserted-by":"publisher","first-page":"703.e1","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology."},{"issue":"1","key":"2025052712494033000_CIT0028","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2018.09.003","article-title":"Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants","volume":"75","author":"Warrick","year":"2019","journal-title":"Eur Urol."},{"issue":"4","key":"2025052712494033000_CIT0029","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol."},{"issue":"4","key":"2025052712494033000_CIT0030","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/BLC-160067","article-title":"The role of PD-L1 expression and intratumoral lymphocytes in response to perioperative chemotherapy for urothelial carcinoma","volume":"2","author":"Erlmeier","year":"2016","journal-title":"Bladder Cancer"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/5\/708\/61429973\/aqae176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/5\/708\/61429973\/aqae176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:50:00Z","timestamp":1748364600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/163\/5\/708\/7953322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,13]]},"published-print":{"date-parts":[[2025,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqae176","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,13]]}}}